Effects of Standard PRP and Extracellular Vesicle-Enriched PRP on Human Gingival Fibroblasts
Comparative Evaluation of Standard Platelet-Rich Plasma (PRP) and Platelet-Derived Extracellular Vesicle-Rich Platelet-Rich Plasma (EV-rich PRP) on Human Gingival Fibroblast Function: An In Vitro Study
The goal of this study is to compare the biological effects of two blood-derived products, standard platelet-rich plasma (PRP) and extracellular vesicle-enriched PRP (EV-enriched PRP), on human gingival (gum) fibroblasts, the cells responsible for gum tissue repair. PRP is a concentrate of platelets prepared from a person's own blood and is used in periodontal and soft tissue regeneration because it releases growth factors. Extracellular vesicles (EVs) are nanometer-sized particles released by platelets that carry proteins and genetic material and may play an important role in tissue healing. No study has yet directly compared standard PRP with an EV-enriched formulation on gingival fibroblasts.
The main questions this study aims to answer are:
- Does EV-enriched PRP increase gingival fibroblast proliferation more than standard PRP?
- Does EV-enriched PRP accelerate gingival fibroblast migration (wound closure) more than standard PRP?
- Do the two products differ in their effects on the expression of growth factor and collagen genes in gingival fibroblasts?
Six healthy, non-smoking adult volunteers aged 20 to 40 years will each give a single blood sample (two tubes, 18 mL in total) from an arm vein. No treatment will be given to the volunteers. Each volunteer's blood will be processed into both standard PRP and EV-enriched PRP, and both products will be tested in the laboratory on a commercially available human gingival fibroblast cell line.
調査の概要
状態
状態
詳細な説明
Study design: This is a laboratory-based study using blood donated by healthy volunteers, with a paired design. Blood from each of six healthy donors will be processed into both standard PRP and EV-enriched PRP, and each donor's PRP will be compared only with the same donor's EV-enriched PRP. Samples will not be pooled; each donor's samples will be analyzed separately. This design aims to minimize the influence of biological variability between donors on the comparison.
Blood collection and product preparation: Two tubes of peripheral venous blood (18 mL in total) will be collected from each volunteer. Standard PRP will be prepared using a commercially available, CE Class IIb certified, single-spin closed-system PRP kit (T-Lab, Turkey; 1150 RCF, 4 minutes). EV-enriched PRP will be prepared using the T-LAB Exomine kit (Turkey), in which Advanced PRX tubes with micro-lyzer blade technology activate platelets and induce EV release through mechanical stress. Stocks of PRP and EV-enriched PRP will be diluted in serum-free DMEM/F12 to final concentrations of 50%, 25%, 10%, 5%, 2.5%, and 1%.
Cell culture: Human gingival fibroblasts (HGF-1, ATCC) will be cultured in DMEM/F12 supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% amphotericin B at 37°C and 5% CO2. Cells at passages 4 to 8 will be used in all experiments.
Cell proliferation assay: HGF-1 cells will be seeded in 96-well plates (2 x 10^3 cells/well) and, after overnight attachment, treated with a negative control (serum-free DMEM), a positive control (DMEM with 10% FBS), six PRP concentrations, and six EV-enriched PRP concentrations (14 groups in total, in technical triplicate). Absorbance will be measured spectrophotometrically at 570 nm at 24, 48, and 72 hours, and relative proliferation (%) will be calculated against the negative control.
Wound healing (scratch) assay: HGF-1 cells will be seeded in 24-well plates (8 x 10^4 cells/well). At 80% confluence a scratch will be created and cells will be treated using the same group layout. Images will be captured with a phase-contrast microscope at baseline, 24 hours, and 48 hours, and the percentage of cell-free area will be calculated with ImageJ software.
Gene expression analysis: After the most effective concentrations for proliferation and migration are identified, HGF-1 cells (5 x 10^4 cells/well, 24-well plates) will be treated with a control (DMEM with 10% FBS) or the optimal PRP and EV-enriched PRP concentrations. On days 3 and 7, expression of TGF-beta1, PDGF-A, PDGF-B, COL1A2, VEGF, and EGF will be analyzed by RT-qPCR, with beta-actin as the reference gene. Relative fold change will be calculated using the 2^-ddCt method.
Sample size: Sample size was based on the large effect sizes reported in the literature for the effects of platelet concentrates on gingival fibroblast function. With a paired t-test, alpha = 0.05, and an assumed effect size of d = 1.5, six donors provide 83% statistical power.
Statistical analysis: Normality will be assessed with the Shapiro-Wilk test. Paired comparisons between PRP and EV-enriched PRP will use the paired t-test or the Wilcoxon signed-rank test, depending on distribution. The combined effects of concentration and time will be evaluated with repeated-measures ANOVA (or the Friedman test) and appropriate post-hoc corrections. p < 0.05 will be considered statistically significant.
Hypothesis: EV-enriched PRP will show superior biological effects on gingival fibroblast proliferation and wound healing compared with conventional PRP.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Kübra Aral, Assoc. Prof.
- 電話番号:+90 533 057 88 01
- メール:kubra.aral@inonu.edu.tr
研究場所
-
-
Battalgazi
-
Malatya、Battalgazi、トルコ(Türkiye)、44100
- Inonu University Faculty of Dentistry
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Systemically healthy, non-smoking adult volunteers aged 20 to 40 years, recruited at Inonu University Faculty of Dentistry, Department of Periodontology (Malatya, Turkey). Individuals receiving treatment for any disease, pregnant or breastfeeding women, and individuals with limited capacity to give informed consent will not be included.
説明
Inclusion Criteria:
- Age 20 to 40 years
- Systemically healthy
- Non-smoker
- Not using anticoagulant medication
- Willing to participate and able to provide written informed consent
Exclusion Criteria:
- History of bleeding disorder or coagulation abnormality
- Use of medications affecting platelet function (e.g., antiplatelet or anticoagulant agents)
- Acute infection
- Pregnancy or breastfeeding
- Systemic disease (e.g., diabetes, autoimmune or hematological disease)
- Age under 20 or over 40 years
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:OTHER
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
|---|
|
Healthy Blood Donors
Six systemically healthy, non-smoking adult volunteers aged 20 to 40 years who are not using anticoagulant or antiplatelet medication. Each participant provides a single peripheral venous blood sample (two tubes, 18 mL in total); no treatment is administered to participants. From each donor's blood, both standard platelet-rich plasma (PRP) and extracellular vesicle-enriched PRP (EV-enriched PRP) are prepared and tested in vitro on human gingival fibroblasts (HGF-1), allowing a paired, within-donor comparison of the two products. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Gingival Fibroblast Proliferation
時間枠:24, 48, and 72 hours after treatment
|
Proliferation of human gingival fibroblasts (HGF-1) treated with standard PRP versus EV-enriched PRP at six concentrations (50%, 25%, 10%, 5%, 2.5%, 1%), measured spectrophotometrically at 570 nm and expressed as relative proliferation (%) compared with the negative control (serum-free DMEM). Each donor's PRP is compared with the same donor's EV-enriched PRP (paired comparison). |
24, 48, and 72 hours after treatment
|
|
Gingival Fibroblast Wound Closure (Scratch Assay)
時間枠:Baseline, 24 hours, and 48 hours after scratch
|
Migration of human gingival fibroblasts (HGF-1) in an in vitro scratch assay after treatment with standard PRP versus EV-enriched PRP at six concentrations, assessed by phase-contrast microscopy and expressed as the percentage of remaining cell-free area calculated with ImageJ software. Each donor's PRP is compared with the same donor's EV-enriched PRP (paired comparison). |
Baseline, 24 hours, and 48 hours after scratch
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Growth Factor and Collagen Gene Expression in Gingival Fibroblasts
時間枠:Day 3 and day 7 after treatment
|
Relative mRNA expression of TGF-beta1, PDGF-A, PDGF-B, COL1A2, VEGF, and EGF in human gingival fibroblasts (HGF-1) treated with the optimal concentrations of standard PRP and EV-enriched PRP (selected from the proliferation and migration assays), compared with control (DMEM with 10% FBS). Expression will be measured by RT-qPCR with beta-actin as the reference gene and reported as relative fold change using the 2^-ddCt method. |
Day 3 and day 7 after treatment
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Antich-Rossello M, Munar-Bestard M, Forteza-Genestra MA, Calvo J, Gaya A, Monjo M, Ramis JM. Evaluation of Platelet-Derived Extracellular Vesicles in Gingival Fibroblasts and Keratinocytes for Periodontal Applications. Int J Mol Sci. 2022 Jul 11;23(14):7668. doi: 10.3390/ijms23147668.
- Nguyen PA, Pham TAV. Effects of platelet-rich plasma on human gingival fibroblast proliferation and migration in vitro. J Appl Oral Sci. 2018 Jul 10;26:e20180077. doi: 10.1590/1678-7757-2018-0077.
- Kobayashi E, Fujioka-Kobayashi M, Sculean A, Chappuis V, Buser D, Schaller B, Dori F, Miron RJ. Effects of platelet rich plasma (PRP) on human gingival fibroblast, osteoblast and periodontal ligament cell behaviour. BMC Oral Health. 2017 Jun 2;17(1):91. doi: 10.1186/s12903-017-0381-6.
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- IU-2026 PRP
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will not be shared publicly because the study involves a small number of healthy donors and the data consist of in vitro laboratory measurements derived from donor blood products. Aggregated results will be reported in the resulting publication, and de-identified laboratory data may be made available by the corresponding author upon reasonable request.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。